ProStrakan is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets. 

ProStrakan´s goal is to build a significant international pharmaceutical company based on a self-sustaining business model. At its most simple, that means bringing products onto the market, either from their R&D portfolio or by licensing, to be sold by their own sales forces. 

The revenues from increasing sales of products will, in turn, provide for greater investment in R&D. Such a business model takes time to achieve by organic growth alone. That's why ProStrakan also seeks appropriate opportunities to grow its commercial operations and to expand its research and development portfolio through corporate and/or product acquisition and through partnering relationships.

ProStrakan's current strategic focus is on

• women's health
• the ageing male
• bone diseases